Literature DB >> 11416781

Postmenopausal hormone use, screening, and breast cancer: characterization and control of a bias.

M M Joffe1, C Byrne, G A Colditz.   

Abstract

Previous investigators have suggested that screening-related biases may explain associations between postmenopausal hormone use and breast cancer. To investigate these biases, we studied postmenopausal women in the Nurses' Health Study from 1988 to 1994. Hormone use is associated with increased subsequent screening. Among women not screened in the previous 2 years, the probability difference, comparing current hormone users with others, for having mammography in the following 2 years is 19.5%; among women previously screened, the difference is 4.9%. These differences persist after control for other factors. If the increase in screening is causal, screening by mammogram could be intermediate in the causal pathway to breast cancer diagnosis. To deal with this problem, we restrict attention to a subset of the cohort in which the effect of postmenopausal hormone use on screening is small (women previously screened). In this subset, the rate ratio comparing breast cancer rates among current postmenopausal hormone users with others is 1.28. In a sensitivity analysis, the bias could not by itself plausibly account for the associations in our data. Our data provide evidence of an association between postmenopausal hormone use and breast cancer that is not solely the product of a detection bias.

Entities:  

Mesh:

Year:  2001        PMID: 11416781     DOI: 10.1097/00001648-200107000-00013

Source DB:  PubMed          Journal:  Epidemiology        ISSN: 1044-3983            Impact factor:   4.822


  16 in total

1.  Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial.

Authors:  Garnet L Anderson; Rowan T Chlebowski; Aaron K Aragaki; Lewis H Kuller; JoAnn E Manson; Margery Gass; Elizabeth Bluhm; Stephanie Connelly; F Allan Hubbell; Dorothy Lane; Lisa Martin; Judith Ockene; Thomas Rohan; Robert Schenken; Jean Wactawski-Wende
Journal:  Lancet Oncol       Date:  2012-03-07       Impact factor: 41.316

Review 2.  Changing concepts: Menopausal hormone therapy and breast cancer.

Authors:  Rowan T Chlebowski; Garnet L Anderson
Journal:  J Natl Cancer Inst       Date:  2012-03-16       Impact factor: 13.506

Review 3.  Menopausal hormone therapy and breast cancer mortality: clinical implications.

Authors:  Rowan T Chlebowski; Garnet L Anderson
Journal:  Ther Adv Drug Saf       Date:  2015-04

4.  Breast Cancer After Use of Estrogen Plus Progestin and Estrogen Alone: Analyses of Data From 2 Women's Health Initiative Randomized Clinical Trials.

Authors:  Rowan T Chlebowski; Thomas E Rohan; JoAnn E Manson; Aaron K Aragaki; Andrew Kaunitz; Marcia L Stefanick; Michael S Simon; Karen C Johnson; Jean Wactawski-Wende; Mary J O'Sullivan; Lucile L Adams-Campbell; Rami Nassir; Lawrence S Lessin; Ross L Prentice
Journal:  JAMA Oncol       Date:  2015-06       Impact factor: 31.777

5.  Variation in Breast Cancer-Risk Factor Associations by Method of Detection: Results From a Series of Case-Control Studies.

Authors:  Brian L Sprague; Ronald E Gangnon; John M Hampton; Kathleen M Egan; Linda J Titus; Karla Kerlikowske; Patrick L Remington; Polly A Newcomb; Amy Trentham-Dietz
Journal:  Am J Epidemiol       Date:  2015-05-05       Impact factor: 4.897

6.  Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study.

Authors:  Rowan T Chlebowski; JoAnn E Manson; Garnet L Anderson; Jane A Cauley; Aaron K Aragaki; Marcia L Stefanick; Dorothy S Lane; Karen C Johnson; Jean Wactawski-Wende; Chu Chen; Lihong Qi; Shagufta Yasmeen; Polly A Newcomb; Ross L Prentice
Journal:  J Natl Cancer Inst       Date:  2013-03-29       Impact factor: 13.506

7.  Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women's Health Initiative Randomized Clinical Trials.

Authors:  Rowan T Chlebowski; Garnet L Anderson; Aaron K Aragaki; JoAnn E Manson; Marcia L Stefanick; Kathy Pan; Wendy Barrington; Lewis H Kuller; Michael S Simon; Dorothy Lane; Karen C Johnson; Thomas E Rohan; Margery L S Gass; Jane A Cauley; Electra D Paskett; Maryam Sattari; Ross L Prentice
Journal:  JAMA       Date:  2020-07-28       Impact factor: 56.272

Review 8.  Estrogen metabolism and breast cancer.

Authors:  Hamed Samavat; Mindy S Kurzer
Journal:  Cancer Lett       Date:  2014-04-28       Impact factor: 8.679

9.  Screening mammography intervals among postmenopausal hormone therapy users and nonusers.

Authors:  Tracy Onega; Todd MacKenzie; Julia Weiss; Martha Goodrich; Linda Titus-Ernstoff
Journal:  Cancer Causes Control       Date:  2009-10-21       Impact factor: 2.506

10.  Mammographic screening and risk factors for breast cancer.

Authors:  Nancy R Cook; Bernard A Rosner; Susan E Hankinson; Graham A Colditz
Journal:  Am J Epidemiol       Date:  2009-10-29       Impact factor: 4.897

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.